Comparison of the efficacy of polyethylene glycol loxenatide injection with empagliflozin in the treatment of early diabetic kidney disease in type 2 diabetes mellitus
Objective To compare the clinical efficacy of polyethylene glycol loxenatide injection(PEX168)with empagliflozin in the treatment of early DKD in T2DM.Methods Sixty patients with early DKD(G2A2 stage)in T2DM who were admitted to the Department of Endocrinology,the First People's Hospital of Chenzhou from February 2020 to February 2021 were selected,and they were divided into the PEX168 group(n=30)and the empagliflozin group(n=30)using randomizednumerical table method,which were given polyethylene glycol loxenatide injection and empagliflozin respectively,and both groups were treated for 24 weeks.Blood glucose indexes(FPG,2 hPG,HbA1c,HOMA-IR),Blood pressure(SBP,DBP),renal function index(UACR,eGFR),BMI,visceral fat area before treatment,and at 12 and 24 weeks post-treatment,and adverse reactions were compared between the two groups.Results After 12 and 24 weeks of treatment,blood glucose indexes(FPG,2 hPG,HbA1c,HOMA-IR)and blood pressure(SBP,DBP)were lower than those before treatment in the two groups(P＜0.05 or P＜0.01),and there were no statistically significant difference between the other indexes of the two groups(P＞0.05).After 12 and 24 weeks of treatment,the eGFR of the two groups were higher than that before treatment,and the UACR,BMI and visceral fat area were lower than those before treatment,and the eGFR of the PEX168 group was higher than that of the empagliflozin group,and the UACR,BMI and visceral fat area were lower than that of the empagliflozin group after 24 weeks of treatment(P＜0.05 or P＜0.01),and the differences in eGFR,UACR,BMI and visceral fat area were not statistically significant when comparing the two groups after 12 weeks of treatment(P＞0.05).There were no serious adverse reactions in both groups.Conclusion Polyethylene glycol loxenatide injection and empagliflozin both have obvious hypoglycemic and nephroprotective effects,but polyethylene glycol losenatide injection has better nephroprotective effects in overweight and abdominal obese patients with early DKD in T2DM.
Type 2 diabetes mellitusDiabetic kidney diseasePolyethylene glycol loxenatide injectionEmpagliflozinGlomerular filtration rateUrine albumin-creatinine ratio
万方数据
维普
